Egypt Hyperlipidemia Drugs Market is Expected to be Dominated by PCSK9 Inhibitors through 2028
Rising
awareness regarding the risks of cardiovascular disease (CVD) brought on by
prolonged hypercholesterolemia is expected to drive the growth of the Egypt hyperlipidemia
drugs market in the coming years.
According to TechSci Research report, “Egypt Hyperlipidemia Drugs - By Region, Competition,
Forecast, and Opportunities, 2028”,
during the projected period, 2024–2028, the Egypt hyperlipidemia drugs market is
anticipated to expand at a remarkable rate.
The Egypt hyperlipidemia drugs market is
driven by factors such as the growing prevalence of hyperlipidemia, rising
awareness about the risks of cardiovascular disease, and the increasing demand
for effective treatments. One of the key trends in the market is the dominance
of PCSK9 inhibitors, which are expected to grow significantly in the coming
years due to their high efficacy, low side-effect profile, and the increasing
demand for innovative treatments. However, the market is also facing challenges
such as high prices, limited availability of advanced therapies in rural areas,
and the lack of awareness about hyperlipidemia among some patient populations.
Recent technological advancements, such as inclisiran, a new siRNA-based
therapy for hyperlipidemia, have shown promise in improving patient outcomes
and are expected to drive further growth in the market.
The COVID-19 pandemic has had a
significant impact on the Egypt hyperlipidemia drugs market. The pandemic has
led to disruptions in the healthcare system, including delays in the diagnosis
and treatment of hyperlipidemia. Additionally, the economic impact of the
pandemic has led to financial constraints for many patients, leading to a
reduction in demand for hyperlipidemia drugs. On the other hand, the pandemic
has also led to an increased awareness of the importance of maintaining good
health, including managing hyperlipidemia. This has led to an increased demand
for hyperlipidemia drugs, as patients are seeking to improve their health and
reduce their risk of complications. The pandemic has also highlighted the
importance of telemedicine and digital health solutions, which have allowed
patients to receive care remotely, without the need for in-person
consultations. This has led to an increase in the adoption of digital health
solutions, including remote monitoring and teleconsultations, which continue even
when the pandemic has subsided.
Browse over XX market data Figures
spread through XX
Pages and an in-depth TOC on "Egypt Hyperlipidemia Drugs Market.”
The Egypt hyperlipidemia drugs market can
be segmented by drug class, distribution channel, and region.
Based on drug class, the market can be segmented
into statins, bile acid sequestrants, cholesterol absorption inhibitors, PCSK9
inhibitors, combination, and others. PCSK9 inhibitors, a type of hyperlipidemia
drug that lowers LDL cholesterol levels, are expected to dominate the growth of
the Egypt hyperlipidemia drugs market in the coming years due to their high
efficacy and low side-effect profile. This drug class has shown promising
results in clinical trials, leading to their approval by regulatory agencies
for use in treating hyperlipidemia. Moreover, PCSK9 inhibitors have also been
found to provide benefits beyond just lowering cholesterol, including reducing
the risk of cardiovascular events. As such, their effectiveness and versatility
make them a highly sought-after treatment option, driving their continued
growth and dominance in the Egypt hyperlipidemia drugs market.
In terms of distribution channel, the
market can be divided into hospital pharmacy, retail pharmacy, and online
pharmacy. Hospital pharmacy is expected to dominate the growth of the Egypt
hyperlipidemia drugs market in the coming years due to the high prevalence of
hyperlipidemia among hospitalized patients. Hospital pharmacies are
well-equipped to manage and dispense complex medication regimens, making them
the preferred distribution channel for specialty drugs used to treat
hyperlipidemia. Additionally, hospital pharmacies are often affiliated with
medical facilities and healthcare providers, making them a convenient option
for patients seeking specialized care. As such, hospital pharmacies are
expected to continue to dominate the Egypt hyperlipidemia drugs market as the
demand for specialized care for hyperlipidemia patients grows.
Based on the region, the market can be
classified into following categories, Cairo, Qalyubia, Alexandria, Port Said,
Giza, and Suez. The Cairo region is expected to dominate the growth of the
Egypt hyperlipidemia drugs market in the coming years due to the high
prevalence of hyperlipidemia in the region. The increasing urbanization and
sedentary lifestyles in Cairo have contributed to the high incidence of
hyperlipidemia among the population. Additionally, Cairo is the most populous
city in Egypt, and its healthcare infrastructure is well-developed, making it a
hub for healthcare services in the country. As such, the demand for
hyperlipidemia drugs in Cairo is expected to continue to grow, driving the
dominance of the Cairo region in the Egypt hyperlipidemia drugs market.
Major companies operating in Egypt hyperlipidemia
drugs market include:
- Amoun Pharmaceutical
Company
- Pharco Corporation
- EIPICO (Egyptian
International Pharmaceutical Industries Company)
- Rameda Pharmaceuticals
- Minapharm
Pharmaceuticals
- Delta Pharma
- Memphis For
Pharmaceutical & Chemical Industries
- Biopharm Group Egypt
Download Sample Report
Customers can
also request for 10% free customization on this report.
“The Egypt hyperlipidemia drugs market
is expected to experience significant growth in the coming years, driven by
several factors. These include the increasing prevalence of hyperlipidemia,
rising awareness about the risks of cardiovascular disease, and the development
of innovative drugs such as PCSK9 inhibitors. However, there are also
challenges that may impact the market's growth, such as high drug prices and
limited access to healthcare services in some areas. Nonetheless, the market is
expected to benefit from ongoing clinical trials aimed at developing new
hyperlipidemia drugs and improving existing treatments. Additionally, emerging trends
such as the increasing use of digital health solutions and telemedicine are
expected to play a significant role in the market's growth.” said Mr. Karan
Chechi, Research Director with TechSci Research, a research-based global
management consulting firm.
“Egypt
Hyperlipidemia Drugs Market, By Drug Class (Statins, Bile Acid Sequestrants,
Cholesterol Absorption Inhibitors, PCSK9 Inhibitors, Combination, Others), By
Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By
Region, Competition, Forecast, & Opportunities, 2028”, has evaluated the future
growth potential of Egypt hyperlipidemia drugs market and provides statistics
& information on market size, structure, and future market growth. The
report intends to provide cutting-edge market intelligence and help decision
makers take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in Egypt hyperlipidemia drugs market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Web: https://www.techsciresearch.com